Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Porter

Showing results (91-100 of 199) with videos related to

Pageof 20
Sort By:
Blood|April 6, 2011
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesRobert J Soiffer, Jennifer Lerademacher, Vincent Ho, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 17, 2002
Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patientsDonald E Tsai, Monica Nearey, Christine L Hardy, et al.
Cytotherapy|November 3, 2018
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomasNirav N Shah, Sarah J Nagle, Drew A Torigian, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceMichael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, et al.
Blood|September 23, 2017
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemiaKaren Thudium Mueller, Shannon L Maude, David L Porter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 3, 2013
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantationAnita J Kumar, Elizabeth O Hexner, Noelle V Frey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantationJohn E Levine, Thomas Braun, Samuel L Penza, et al.
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Critical Care Medicine|September 16, 2016
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaJulie C Fitzgerald, Scott L Weiss, Shannon L Maude, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 17, 2020
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 PandemicVeronika Bachanova, Michael R Bishop, Parastoo Dahi, et al.
Pageof 20

Showing results (91-100 of 199) with videos related to

Sort By:
Pageof 20
Blood|April 6, 2011
Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignanciesRobert J Soiffer, Jennifer Lerademacher, Vincent Ho, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 17, 2002
Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patientsDonald E Tsai, Monica Nearey, Christine L Hardy, et al.
Cytotherapy|November 3, 2018
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomasNirav N Shah, Sarah J Nagle, Drew A Torigian, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceMichael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, et al.
Blood|September 23, 2017
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemiaKaren Thudium Mueller, Shannon L Maude, David L Porter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 3, 2013
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantationAnita J Kumar, Elizabeth O Hexner, Noelle V Frey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantationJohn E Levine, Thomas Braun, Samuel L Penza, et al.
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Critical Care Medicine|September 16, 2016
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic LeukemiaJulie C Fitzgerald, Scott L Weiss, Shannon L Maude, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 17, 2020
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 PandemicVeronika Bachanova, Michael R Bishop, Parastoo Dahi, et al.
Pageof 20